Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: We would like to raise concerns
about a possible bias in the cost-effectiveness analysis by Drs O’Brien
and Gage.1 To calculate quality-adjusted survival,
the authors used results of a previous survey of 83 patients with atrial fibrillation,2 which estimated the mean utility of warfarin therapy
to be 0.987 and the mean utility of aspirin therapy to be 0.998. We believe
that the utility of warfarin therapy may be overestimated.
Perret-Guillaume C, Wahl D. Cost-effectiveness of Ximelagatran for Stroke Prevention. JAMA. 2005;293(23):2860-2861. doi:10.1001/jama.293.23.2860